Results 51 to 60 of about 128,640 (296)
How glucagon-like peptide 1 receptor agonists work
Endocrine Connections, 2021 In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show ...
Christine Rode Andreasen +3 more
doaj +1 more source
Insulin-like growth factor-1 is a negative modulator of glucagon secretion [PDF]
, 2017 Glucagon secretion involves a combination of paracrine, autocrine, hormonal, and autonomic neural mechanisms. Type 2 diabetes often presents impaired glucagon suppression by insulin and glucose.
Andreozzi, F +6 more
core +1 more source
GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
Frontiers in Endocrinology, 2021 The glucagon-like peptide-1 receptor (GLP-1R) is a G-protein-coupled receptor (GPCR) whose activation results in suppression of food intake and improvement of glucose metabolism. Several receptor interacting proteins regulate the signaling of GLP-1R such
Seunghun P. Lee +7 more
doaj +1 more source
New perspectives on the use of glucagon-like peptide 1 in diseases of the central nervous system
Current Issues in Pharmacy and Medical Sciences, 2023 Glucagon-like peptide 1 is a neuromodulatory peptide that regulates the carbohydrate metabolism. It can cross the blood-brain barrier, and, indeed, while mostly produced in the distal small intestine and colon, it is also synthesized in the nucleus of ...
Lupina Malgorzata, Listos Joanna
doaj +1 more source
Glucagon-Like Peptide-1 and Diabetes [PDF]
Experimental Diabetes Research, 2011 This special issue was focused on the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. This gastrointestinal hormone, which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake.
openaire +2 more sources
Proglucagon-derived peptides do not significantly affect acute exocrine pancreas in rat
, 2015 Reports have suggested a link between treatment with glucagon-like peptide 1 (GLP-1) analogs and an increased risk of pancreatitis. Oxyntomodulin, a dual agonist of both GLP-1 and glucagon receptors, is currently being investigated as a potential ...
Akalestou, E +5 more
core +1 more source
Intravenous glucagon like peptide-1 infusion does not affect dry matter intake or hypothalamic mRNA expression of neuropeptide Y, agouti related peptide and proopiomelanocortin in wethers [PDF]
, 2014 The objectives of the present study were to determine the effects of jugular vein infusions of glucagon like peptide-1 (GLP-1) and dietary fat inclusion on dry matter intake, nutrient digestibility and hypothalamic mRNA concentration of neuropeptide Y ...
Loerch, S. C. +2 more
core +1 more source
Dapagliflozin prevents methylglyoxal‐induced retinal cell death in ARPE‐19 cells
FEBS Open Bio, EarlyView.Diabetic macular oedema is a diabetes complication of the eye, which may lead to permanent blindness. ARPE‐19 are human retinal cells used to study retinal diseases and potential therapeutics. Methylglyoxal is a compound increased in uncontrolled diabetes due to elevated blood glucose.
Naina Trivedi +7 more
wiley +1 more source
In Vivo Imaging of Transplanted Islets with ^(64)Cu-DO3A-VS-Cys^(40)-Exendin-4 by Targeting GLP-1 Receptor [PDF]
, 2011 Glucagon-like peptide 1 receptor (GLP-1R) is highly expressed in pancreatic islets, especially on β-cells. Therefore, a properly labeled ligand that binds to GLP-1R could be used for in vivo pancreatic islet imaging.
Bading, James R. +11 more
core +2 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi +9 more
wiley +1 more source